玄七健骨片 | China Drugs ListXuanqi Jiangu tablets | China Drugs List

本页为公开参考信息,不构成医疗建议、处方或药品供应要约。请向持证专业人士确认当前批准情况、可获得性及适用性。

药品类型
中成药Traditional Chinese medicine
治疗领域
肌肉骨骼Musculoskeletal
公开来源记录的适应症
活血舒筋,通脉止痛,补肾健骨。用于轻中度膝骨关节炎中医辨证属筋脉瘀滞证的症状改善,症见膝关节局部疼痛,活动不利,局部肿胀、压痛、痛有定处、僵硬,活动受限,舌质暗红或有瘀斑,苔薄或薄白,脉滑或弦。TCM actions: invigorates blood, relaxes the sinews, unblocks the channels, relieves pain, tonifies the kidney and strengthens bones. For improvement of symptoms in mild-to-moderate knee osteoarthritis with the TCM pattern of stagnation in the sinews and channels. Symptoms include localized knee pain, impaired movement, swelling, tenderness, fixed-site pain, stiffness and restricted movement; a dark-red tongue or stasis spots with a thin or thin white coating; and a slippery or wiry pulse.
适应症来源与口径
来源日期: 2024. 适应症转录自国家医保局公开的企业申报资料;不代表已核实完整的现行说明书。 新增适应症可能由较新的公告或申报资料支持,而非旧版完整说明书;请查看适应症来源。Source date(s): 2024. Indications transcribed from the public NHSA manufacturer submission; this is not verification of the complete current label. Additional indications may be supported by newer announcements or submissions rather than the older full label; see the indication sources.
说明书信息局限
适应症已与官方公开申报资料核对。尚未取得完整原始说明书。Indications checked against an official public submission. The full original prescribing information is still unavailable.
中国可获得性状态
已核实中国历史批准记录;尚未逐项核查每个产品目前是否持续上市销售。Historical Chinese approval verified; current continuous market availability has not been checked for every product.
海外状态
待逐一核查各市场。Market-by-market verification pending.
医保分类
已纳入国家医保(乙类)Included in national insurance (Category B)
医保版本
2025版;2026年1月1日起执行2025 edition; effective 1 January 2026
医保限制
该目录条目未另列限定;仍须遵守目录凡例及法定适应症No additional restriction is specified for this formulary entry. General formulary rules and legally approved indications still apply.
医保期限
2025-01-01 至 2026-12-312025-01-01 to 2026-12-31
医保核查说明
按成分/剂型名称精确或标准化匹配。报销仍取决于剂型及目录所列支付限制。Matched by exact or normalized ingredient/formulation name. Reimbursement still depends on the dosage form and listed payment restrictions.

来源

打开交互详情、公开价格与讨论